Biocon Biologics is a global leader in biosimilars and insulin production and is among the top three global players for rh- Insulin and Insulin Glargine, providing over 9.2 billion doses of insulin ...

The FDA approval of KIRSTY expands Biocon Biologics' biosimilar insulin portfolio, which also includes the first approved interchangeable biosimilar, Semglee® (Insulin Glargine-yfgn Injection).

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of ...

The FDA approval of KIRSTY expands Biocon Biologics’ biosimilar insulin portfolio, which also includes the first approved interchangeable biosimilar, Semglee® (Insulin Glargine-yfgn Injection).

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States ...

Once-weekly IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Zydus has received final approval from the USFDA for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes.

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted approval for 100 mg/10mL multi-dose vial of ...

Civica has switched insulin suppliers, faced delays in supply chains and slowly staffed up its plant.

Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval. Serious side effects reported with Merilog include hypoglycemia, severe allergic ...